Bertil Lindmark

The Amazing Biological Revolution and The Amazing New Health Care Bertil Lindmark

Bertil Lindmark (MD, PhD) is a Swedish professor in molecular epidemiology. He has spent years studying the human biology. His work with some of the top pharmaceuticals in the world such as Astra and AstraZeneca speaks for itself. Not only that, he has played an instrumental role in developing the billion-dollar selling drug Symbicort for asthma and COPD. In Japan, he led the Clinical Development before he moved on to become the global head of R& D at Almirall in Barcelona, Spain. There he developed the second long-acting antimuscarinic to the market in the US and in EU, and several other compounds, which were acquired by AstraZeneca in 2014.




He then became the Chief Medical Officer of ASLAN Pharmaceuticals in Singapore and led the development of several oncology and dermatology compounds. In 2019, he started at eTheRNA Immunotherapies in Belgium as the CMO leading the clinical development of cancer immunotherapies using similar technology as Moderna and BionTech.




Since 2020, Bertil Lindmark has been serving as the CMO Galecto Biotech in Copenhagen, Denmark. His focus here is to use antagonists of galecting-3 which is a central pro-inflammatory and pro-fibrotic molecule to develop medicines against fibrosis and cancer.